Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
BUSINESS
Daiichi Sankyo’s ADC U3-1402 Scores 39% ORR for EGFR-Mutated NSCLC in PI
Daiichi Sankyo’s HER3 directed antibody drug conjugate (ADC) patritumab deruxtecan (U3-1402) showed a 39% objective response rate in a global PI clinical study in patients with EGFR-mutated metastatic or unresectable non-small cell lung cancer (NSCLC), according to the latest data…
To read the full story
Related Article
- Daiichi Sankyo’s HER3 ADC Hits PFS Goal in EGFR-Mutant Lung Cancer
September 18, 2024
- FDA Snubs Daiichi Sankyo’s HER3 ADC over Third-Party Manufacturing Issue
June 28, 2024
- Daiichi’s HER3 ADC Gets Priority Review in US for 3rd Line EGFR-Mutated NSCLC
December 26, 2023
- Daiichi Sankyo’s HER3 ADC Posts Positive PII Data in 3rd Line NSCLC, US Filing Eyed by March
September 12, 2023
- Daiichi Sankyo’s HER3 ADC Enters PIII for EGFR-Mutated NSCLC
August 10, 2022
BUSINESS
- Dermatologist Hails Bimzelx as New Option for HS: UCB Seminar
November 27, 2024
- Shionogi Chided for Violating Promotion Guidelines with Actair
November 27, 2024
- Eisai, NCNP Tie Up for APOE Genetic Testing Research Sponsored by AMED
November 27, 2024
- Oncolys Seeks Marketing License for Regenerative Medicine in Japan
November 27, 2024
- Otsuka Files Esperion’s Cholesterol Fighter in Japan
November 27, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…